<DOC>
	<DOCNO>NCT00887380</DOCNO>
	<brief_summary>The purpose study determine whether start anastrozole prior radiotherapy , take radiotherapy , decrease local recurrence breast cancer post-menopausal woman comparison wait radiotherapy commence anastrozole .</brief_summary>
	<brief_title>STARS Breast Trial ( Study Anastrozole Radiotherapy Sequencing )</brief_title>
	<detailed_description>Adjuvant radiotherapy well establish primary modality enhance local control breast cancer . The use adjuvant hormone therapy tamoxifen show improve local control relatively minor amount enhance local control adjuvant radiotherapy . There , however , conflict invitro clinical data regard effect different sequence tamoxifen radiotherapy term local control enhancement radiotherapy toxicity . Aromatase inhibitor anastrozole establish class drug superior tamoxifen control estrogen dependent breast cancer overall well tolerate exception great bone loss . As key question whether sequence aromatase inhibitor anastrozole alters local control act enhancer radiation breast cancer cell kill , therefore aim study compare 3 month anastrozole prior radiotherapy versus 3 month anastrozole radiotherapy specific objective reduce baseline ratio in-field radiotherapy failure 6 % 3 % .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Estrogen Antagonists</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Women age 18 year old Post total mastectomy lumpectomy . All plan cancer resection surgery complete . Histologic pathologic report must verify either : No tumour contact inked margin surgically remove tissue , Focal involvement ( &lt; 2mm front ) margin deep ( posterior part ) breast surgeon confirm surgery extend deep fascia , Focal involvement ( &lt; 2mm front ) margin superficial ( anterior part breast subcutaneous ) surgeon confirm surgery extend subcutis NB : In case focally involved deep superficial margin , medical record multidisciplinary meeting note correspondence surgeon must indicate surgeon confirms surgery extend deep fascia subcutis appropriate . Patients routinely receive lumpectomy bed boost conserve breast set focal superficial focal deep involvement define . Tumour oestrogen receptor and/or progesterone receptor positive ( ≥10 % cell positive ) . Radiotherapy yet commence Planned radiotherapy dose prescribe ICRU reference point irradiate breast / chest wall volume least biological equivalent 45 Gy 25 fraction . ( BED Gy4 ≥ 65 , BED Gyx=D ( 1+n/x ) D=total dose , n=dose per fraction , x=alpha beta ratio , Gy4 select appropriate alphabeta ratio human breast cancer line ) An ECOG performance status score 2 less . Female post menopausal show satisfy least one follow criterion ( per ATAC study criteria16 ) : bilateral oophorectomy age great 60 age 4559 year intact uterus amenorrhoeic least 12 month Amenorrhoeic le 12 month follicle stimulate hormone ( FSH ) level within post menopausal range ( include patient amenorrhoea due chemotherapy , LHRH use hormone replacement follow hysterectomy ) Note : recommended woman age 45 render menopausal chemotherapy enrol onto stratum switch Tamoxifen initial 3 month anastrozole . Is receive chemotherapy , receive chemotherapy course complete least 3 week prior commence radiotherapy Unilateral treatment Has provide write informed consent participation trial Previous radiotherapy area treat Previous invasive malignancy within 5 year current breast cancer diagnosis exception cervix insitu skin cancer melanoma . Patients clinical evidence metastatic disease . Previous hormonal breast cancer therapy . Ongoing hormone replacement therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Timing Radiotherapy</keyword>
	<keyword>Local control</keyword>
</DOC>